Organon to present real-world effectiveness analysis of VTAMA cream in atopic dermatitis at 2026 Fall Clinical Dermatology Conference

• Organon flagged a new real-world analysis of VTAMA (tapinarof) cream for atopic dermatitis, scheduled for presentation at a 2026 dermatology meeting.
• The study assessed effectiveness in routine care, focusing on clinician-reported disease improvement and patient-reported itch relief.
• The update supports VTAMA’s positioning beyond controlled trials, targeting broader adoption in adult and pediatric atopic dermatitis use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001161544) on October 01, 2026, and is solely responsible for the information contained therein.